186 related articles for article (PubMed ID: 28232234)
21. JAK2 V617F stimulates proliferation of erythropoietin-dependent erythroid progenitors and delays their differentiation by activating Stat1 and other nonerythroid signaling pathways.
Shi J; Yuan B; Hu W; Lodish H
Exp Hematol; 2016 Nov; 44(11):1044-1058.e5. PubMed ID: 27473563
[TBL] [Abstract][Full Text] [Related]
22. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.
Zaleskas VM; Krause DS; Lazarides K; Patel N; Hu Y; Li S; Van Etten RA
PLoS One; 2006 Dec; 1(1):e18. PubMed ID: 17183644
[TBL] [Abstract][Full Text] [Related]
23. Calreticulin mediated glucocorticoid receptor export is involved in beta-catenin translocation and Wnt signalling inhibition in human osteoblastic cells.
Olkku A; Mahonen A
Bone; 2009 Apr; 44(4):555-65. PubMed ID: 19100874
[TBL] [Abstract][Full Text] [Related]
24. Changes in the glucocorticoid receptor and Ca²⁺/calreticulin-dependent signalling pathway in the medial prefrontal cortex of rats with post-traumatic stress disorder.
Wen L; Han F; Shi Y
J Mol Neurosci; 2015 May; 56(1):24-34. PubMed ID: 25407822
[TBL] [Abstract][Full Text] [Related]
25. Application of mutant JAK2V617F for in vitro generation of red blood cells.
Lee SA; Kim JY; Choi Y; Kim Y; Kim HO
Transfusion; 2016 Apr; 56(4):837-43. PubMed ID: 26646156
[TBL] [Abstract][Full Text] [Related]
26. Usefulness of JAK2V617F mutation in distinguishing idiopathic erythrocytosis from polycythemia vera.
Rossi D; Cortini F; Deambrogi C; Barbieri C; Cerri M; Franceschetti S; Conconi A; Capello D; Gaidano G
Leuk Res; 2007 Jan; 31(1):97-101. PubMed ID: 16620973
[TBL] [Abstract][Full Text] [Related]
27. HLA-G turns off erythropoietin receptor signaling through JAK2 and JAK2 V617F dephosphorylation: clinical relevance in polycythemia vera.
Menier C; Guillard C; Cassinat B; Carosella ED; Rouas-Freiss N
Leukemia; 2008 Mar; 22(3):578-84. PubMed ID: 18059484
[TBL] [Abstract][Full Text] [Related]
28. Somatic mutations of calreticulin in myeloproliferative neoplasms.
Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
[TBL] [Abstract][Full Text] [Related]
29. The JAK-STAT signaling pathway is differentially activated in CALR-positive compared with JAK2V617F-positive ET patients.
Lau WW; Hannah R; Green AR; Göttgens B
Blood; 2015 Mar; 125(10):1679-81. PubMed ID: 25745188
[No Abstract] [Full Text] [Related]
30. Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation.
Elf S; Abdelfattah NS; Chen E; Perales-Patón J; Rosen EA; Ko A; Peisker F; Florescu N; Giannini S; Wolach O; Morgan EA; Tothova Z; Losman JA; Schneider RK; Al-Shahrour F; Mullally A
Cancer Discov; 2016 Apr; 6(4):368-81. PubMed ID: 26951227
[TBL] [Abstract][Full Text] [Related]
31. Role of the clathrin adaptor PICALM in normal hematopoiesis and polycythemia vera pathophysiology.
Ishikawa Y; Maeda M; Pasham M; Aguet F; Tacheva-Grigorova SK; Masuda T; Yi H; Lee SU; Xu J; Teruya-Feldstein J; Ericsson M; Mullally A; Heuser J; Kirchhausen T; Maeda T
Haematologica; 2015 Apr; 100(4):439-51. PubMed ID: 25552701
[TBL] [Abstract][Full Text] [Related]
32. Alox5 Blockade Eradicates JAK2V617F-Induced Polycythemia Vera in Mice.
Chen Y; Shan Y; Lu M; DeSouza N; Guo Z; Hoffman R; Liang A; Li S
Cancer Res; 2017 Jan; 77(1):164-174. PubMed ID: 27784744
[TBL] [Abstract][Full Text] [Related]
33. Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET).
Zhao S; Zhang X; Xu Y; Feng Y; Sheng W; Cen J; Wu D; Han Y
Int J Med Sci; 2016; 13(1):85-91. PubMed ID: 26917989
[TBL] [Abstract][Full Text] [Related]
34. TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients.
Trifa AP; Bănescu C; Tevet M; Bojan A; Dima D; Urian L; Török-Vistai T; Popov VM; Zdrenghea M; Petrov L; Vasilache A; Murat M; Georgescu D; Popescu M; Pătrinoiu O; Balea M; Costache R; Coleș E; Șaguna C; Berbec N; Vlădăreanu AM; Mihăilă RG; Bumbea H; Cucuianu A; Popp RA
Br J Haematol; 2016 Jul; 174(2):218-26. PubMed ID: 27061303
[TBL] [Abstract][Full Text] [Related]
35. Calreticulin exon 9 mutations in myeloproliferative neoplasms.
Ha JS; Kim YK
Ann Lab Med; 2015 Jan; 35(1):22-7. PubMed ID: 25553276
[TBL] [Abstract][Full Text] [Related]
36. JAK2V617F and calreticulin mutations in recurrent venous thromboembolism: results from the EDITH prospective cohort.
Ianotto JC; Chauveau A; Mottier D; Ugo V; Berthou C; Lippert E; Delluc A
Ann Hematol; 2017 Mar; 96(3):383-386. PubMed ID: 27766390
[TBL] [Abstract][Full Text] [Related]
37. [Correlations of JAK2V617F point mutation with clinical and laboratory features in patients with polycythemia vera].
Shen YF; Xia J; Lu MZ; Jiang YQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):121-4. PubMed ID: 19236761
[TBL] [Abstract][Full Text] [Related]
38. Congenital JAK2V617F polycythemia vera: where does the genotype-phenotype diversity end?
Kelly K; McMahon C; Langabeer S; Eliwan H; O'Marcaigh A; Smith OP
Blood; 2008 Nov; 112(10):4356-7. PubMed ID: 18988882
[No Abstract] [Full Text] [Related]
39. Interferon α-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation.
Huang BT; Zeng QC; Zhao WH; Li BS; Chen RL
Leuk Res; 2014 Oct; 38(10):1177-83. PubMed ID: 25069759
[TBL] [Abstract][Full Text] [Related]
40. [Correlation of JAK2V617F mutation burden with clinical features in patients with polycythemia vera and essential thrombocythemia].
Liu HX; Tong CR; Cai P; Teng W; Wang H; Zhang Y; Zhu P
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):742-5. PubMed ID: 19549399
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
